fbpx

Updated Guidelines For Treatment of Adolescent ADHD

The American Academy of Pediatrics (AAP) has revised the guidelines for the care of children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) which offers clinicians updated information and opportunities as they work towards providing treatment plans for patients in their care.

Caring for patients with ADHD is complex, and according to the updated treatment models, occurs best in a patient-centered medical home. These new guidelines have been updated from 2011, and can serve as sources of current applications and information for primary care pediatricians, nurse practitioners, physician assistants, and family medicine practices.

Establishing the diagnosis, these guidelines are based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).  While the DSM-5 guidelines are similar to those of 2011, there are two noteworthy exceptions.  Fewer problem behaviors for those age 17 and over are required, and evidence that symptoms began before the age of 12 years instead of age 7.

Also remaining essentially unchanged are the recommended courses of treatments for ADHD. Stimulant medications amphetamines and methylphenidate in various forms are typically the initial approach to counteracting the symptoms of this disorder. Additions included an increase in the number of extended-release forms of stimulant medications, such as Atomexetine, which remains a secondary alternative medication.

Alpha-2 agonists guanfacine and clonidine also continue to be preferred methods of secondary alternative medications.  These extended-release medications are also approved by the Food and Drug Administration as adjuvant treatments.

While behavior therapy is recommended as the first line treatment approach for preschoolers, it is noted in the new guidelines that descriptions of ‘behavior therapy’ for children remain vague, and more detailed treatment plans should be identified.

The predominant studies that were reviewed included recommendations for parents and caregivers that describe behavior management tactics for preschoolers diagnosed with ADHD. Valuing parent and teacher training in behavior management for high school aged children, several included studies outlined the importance of a continuum of care.

Additional concerns touch on the challenges that can be experienced by clinicians when seeking to implement these guidelines, including poor paediatric training in mental health, limited consultative services, and barriers to communication with schools.

The Drug Law Journal provides a wealth of information on updates to medical and mental health guidelines, pertinent information on drug recalls and lawsuits, and current treatment approaches for ADHD diagnosis as well as other health related topics. Staying informed and updated on current findings is an important piece of ensuring the best care is received.

Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.